BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 10080603)

  • 1. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
    Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H
    J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.
    Shiah HS; Cheng AL; Hsu C; Hsu CH; Liu TW; Chang JY; Jan CM; Chao Y; Yu WL; Chuang TR; Whang-Peng J; Chen LT
    J Gastroenterol Hepatol; 2006 Mar; 21(3):531-6. PubMed ID: 16638094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.
    Ch'ang HJ; Wang CC; Cheng AL; Hsu C; Lu YS; Chang MC; Lin JT; Wang HP; Shiah HS; Liu TW; Chang JY; Whang-Peng J; Chen LT
    J Gastroenterol Hepatol; 2006 May; 21(5):874-9. PubMed ID: 16704539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
    Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
    Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
    Louvet C; André T; Hammel P; Selle F; Landi B; Cattan S; Fonck M; Flesch M; Colin P; Balosso J; Ruszniewski P; de Gramont A
    Ann Oncol; 2001 May; 12(5):675-9. PubMed ID: 11432627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.
    Talamonti MS; Catalano PJ; Vaughn DJ; Whittington R; Beauchamp RD; Berlin J; Benson AB
    J Clin Oncol; 2000 Oct; 18(19):3384-9. PubMed ID: 11013279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
    Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
    Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients.
    Shan YS; Lin PW
    Hepatogastroenterology; 2007; 54(79):2141-5. PubMed ID: 18251177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Carrato A; Fernández-Martos C; Antón-Torres A; Massutí T; Barneto I; García-Conde J; Barón JM; Díaz-Rubio E
    Ann Oncol; 1996 Aug; 7(6):581-5. PubMed ID: 8879371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
    Okusaka T; Ishii H; Funakoshi A; Ueno H; Furuse J; Sumii T
    Jpn J Clin Oncol; 2006 Sep; 36(9):557-63. PubMed ID: 16870696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
    Roehrig S; Wein A; Albrecht H; Konturek PC; Reulbach U; Männlein G; Wolff K; Ostermeier N; Hohenberger W; Hahn EG; Boxberger F
    Med Sci Monit; 2010 Mar; 16(3):CR124-131. PubMed ID: 20190682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.
    Barone C; Cassano A; Corsi DC; Pozzo C; Longo R; Schinzari G; Quirino M; Battelli C; Basso M
    Oncology; 2003; 64(2):139-45. PubMed ID: 12566911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer.
    Novarino A; Chiappino I; Bertelli GF; Heouaine A; Ritorto G; Addeo A; Bellone G; Merlano M; Bertetto O
    Ann Oncol; 2004 Mar; 15(3):474-7. PubMed ID: 14998851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no. 1 (LOA-1).
    Rinaldi DA; Lormand NA; Brierre JE; Cole JL; Stagg MP; Fontenot MF; Buller EJ; Rainey JM
    Am J Clin Oncol; 2000 Feb; 23(1):78-82. PubMed ID: 10683085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
    Rauch DP; Maurer CA; Aebi S; Pampallona S; Friess H; Ludwig CU; Büchler MW; Borner MM
    Oncology; 2001; 60(1):43-8. PubMed ID: 11150907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
    Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.